Clinical Trial Update: A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis. [Phase 1]

View source ↗

Summary

Phase 1 relative bioavailability study of Valcyte (valganciclovir) in lung transplant recipients with or without cystic fibrosis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections

Drugs mentioned

• Valcyte (valganciclovir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Cytomegalovirus Infections | Phase 1 | Status: COMPLETED | Results posted: 2015-12-31